Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Cash from Financing Activities (2019 - 2025)

Cyclerion Therapeutics (CYCN) has 5 years of Cash from Financing Activities data on record, last reported at $1.8 million in Q3 2025.

  • For Q3 2025, Cash from Financing Activities changed N/A year-over-year to $1.8 million; the TTM value through Sep 2025 reached $3.1 million, changed N/A, while the annual FY2023 figure was $5.0 million, 17224.14% up from the prior year.
  • Cash from Financing Activities reached $1.8 million in Q3 2025 per CYCN's latest filing, up from -$130000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $30.6 million in Q2 2021 and bottomed at -$130000.0 in Q2 2025.
  • Average Cash from Financing Activities over 3 years is $3.8 million, with a median of $43000.0 recorded in 2021.
  • Peak YoY movement for Cash from Financing Activities: surged 2600.0% in 2021, then tumbled 99.94% in 2022.
  • A 3-year view of Cash from Financing Activities shows it stood at $85000.0 in 2021, then tumbled by 85.88% to $12000.0 in 2022, then soared by 15116.67% to $1.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $1.8 million in Q3 2025, -$130000.0 in Q2 2025, and $1.4 million in Q1 2025.